Figure S1. Box plot for the simulated target saturation over time after DARA SC monotherapy or DARA IV monotherapy.

DARA, daratumumab; SC, subcutaneous; IV, intravenous.

Note: Black arrows represent dose events.
Figure S2. Simulated total clearance and linear clearance versus time profiles for DARA SC and DARA IV for monotherapy dosing schedule\textsuperscript{a} based on typical values of final model parameters.

DARA, daratumumab; SC, subcutaneous; IV, intravenous.

Note: Black arrows represent dose events.

\textsuperscript{a}Approved dose schedule consisted of weekly administration for 8 weeks (8 doses), every 2 weeks for 16 weeks (8 doses), and every 4 weeks thereafter (eg, 8 doses).
Figure S3. Simulated DARA $C_{\text{trough}}$ after 6 weekly doses of DARA SC 1,800 mg monotherapy or combination therapies. DARA, daratumumab; $C_{\text{trough}}$, predicted trough concentration; SC subcutaneous; D-VRd, daratumumab SC plus bortezomib/lenalidomide/dexamethasone; D-VMP, DARA SC plus bortezomib/melphalan/prednisone; D-Rd, DARA SC plus lenalidomide/dexamethasone.
Figure S4. ORR in relation to DARA maximum $C_{\text{trough}}$ (by Quartiles) at the end of weekly dosing for combination therapies.

ORR, overall response rate; DARA, daratumumab; $C_{\text{trough}}$, predicted trough concentration; D-VRd, daratumumab SC plus bortezomib/lenalidomide/dexamethasone; D-VMP, DARA SC plus bortezomib/melphalan/prednisone; D-Rd, DARA SC plus lenalidomide/dexamethasone; SC subcutaneous; Q, quartile.

Note: The quartiles for maximum $C_{\text{trough}}$ are: Q1 (0.1-428 μg/mL), Q2 (428-548 μg/mL), Q3 (548-662 μg/mL), and Q4 (662-1210 μg/mL).